CytomX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Deficit
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income/(Loss) | Deficit | Deficit | |
| Balance at December 31, 2021 | 65,392,758 | $1 | $623,344 | $(242) | $(623,562) | $(459) |
| Exercise of stock options and release of RSUs | 430,096 | — | 99 | — | — | 99 |
| Issuance of common stock under the Employee Stock Purchase Plan | 405,192 | — | 549 | — | — | 549 |
| Stock-based compensation | — | — | 13,125 | — | — | 13,125 |
| Other comprehensive income | — | — | — | 252 | — | 252 |
| Net loss | — | — | — | — | (99,317) | (99,317) |
| Balance at December 31, 2022 | 66,228,046 | 1 | 637,117 | 10 | (722,879) | (85,751) |
| Exercise of stock options and release of RSUs | 675,864 | — | 26 | — | — | 26 |
| Issuance of common stock under the Employee Stock Purchase Plan | 406,928 | — | 535 | — | — | 535 |
| Issuance of pre-funded warrants and warrants, net of issuance cost | — | — | 29,669 | — | — | 29,669 |
| Stock-based compensation | — | — | 8,558 | — | — | 8,558 |
| Other comprehensive income | — | — | — | 85 | — | 85 |
| Net loss | — | — | — | — | (569) | (569) |
| Balance at December 31, 2023 | 67,310,838 | $1 | $675,905 | $95 | $(723,448) | $(47,447) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.